Top S&P500 movers in Tuesday's session

Argus has downgraded Illumina (ILMN) to hold from buy citing falling margins and worsening outlook.

Outlays from the National Institutes of Health ((NIH)) for December 2022 decreased ~4% Y/Y (-35% versus November 2022), according to report from Baird Equity Research.December 2022...

Sharp Tesla price cuts and some notable earnings were in focus.

Illumina may have to pay a fine of 10% of its annual turnover to the EU as a penalty for closing its 2021 acquisition of GRAIL without receiving antitrust clearance,, Reuters reported.

U.S. life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said. Last month Illumina defended its case before senior European Commission and national competition officials at a closed hearing but failed to convince them, the people said. Illumina, which last year set aside $453 million for a potential EU fine, said it would appeal against any fine.

U.S. life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said.

Illumina (ILMN) closed down 6% on Tuesday after its 2023 outlook came in below expectations.